Compare Invesco DB Commodity Index Tracking Fund (DBC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Commodity Index Tracking Fund vs Sana Biotechnology Inc — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $33.07 (market cap $1.92B), while Sana Biotechnology Inc trades at $2.84 (market cap $836.71M). The key difference: Invesco DB Commodity Index Tracking Fund is far larger — about 2.3× Sana Biotechnology Inc's market cap, and Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Commodity Index Tracking Fund for 60 Days and Sana Biotechnology Inc for 23 Days on average.
| DBC | SANA | |
|---|---|---|
Market Cap | $1.92B | $836.71M |
Volume | 1,375,556 | 4,507,444 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $33.68 | $5.92 |
52-Week Low | $22.07 | $2.68 |
Typical Hold Time | 60 Days | 23 Days |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBC trades at $32.51, down 0.55% today, with a bullish technical signal from moving averages. The company reported $82.59M revenue and $22.38M net income for 2024, showing improved profitability with a 27.1% margin. Cash flow from operations was strong at $431.54M, though total assets declined from $2.7B in 2021 to $1.29B currently. Technical indicators show support at $32 and resistance at $33.
DBC demonstrates solid operational cash generation despite asset base contraction. The zero-debt balance sheet provides financial stability, but declining revenue from 2023's $108M raises growth concerns. Current valuation metrics remain undisclosed, requiring deeper analysis. The stock's technical strength suggests near-term upside potential if fundamental performance stabilizes.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
